Savara has patented a method for treating heart failure using inorganic nitrite, specifically sodium nitrite, through inhalation. The method involves administering a therapeutically effective dose without causing significant changes in blood pressure or heart rate. GlobalData’s report on Savara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Savara, Nebulizers and atomisers was a key innovation area identified from patents. Savara's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of heart failure using inhaled inorganic nitrite
A recently granted patent (Publication Number: US11986493B2) discloses a method for decreasing pulmonary capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure in a subject by administering inorganic nitrite through inhalation. The method involves an escalated titrated dose of inorganic nitrite that does not cause a significant drop in systemic blood pressure or an increase in heart rate. This approach is particularly beneficial for conditions such as pulmonary hypertension associated with various heart failures, interstitial lung disease, pulmonary arterial hypertension, and sleep-disordered breathing-related pulmonary hypertension.
The patent claims specify the use of inorganic nitrite in liquid or dry powder formulations, with sodium nitrite being a preferred option. The method involves administering escalating doses of nitrite, leading to a final emitted dose ranging from about 75 mg to 90 mg, resulting in a plasma concentration of nitrite between 4 to 15 micromolar. Additionally, the administration of inorganic nitrite is shown to improve cardiac index and increase exercise capacity in subjects. This method is particularly useful for individuals who are non-responsive to inhaled nitric oxide and those with conditions like pulmonary arterial hypertension, especially when associated with connective tissue diseases like scleroderma, as well as heart failure with preserved or reduced ejection fraction.
To know more about GlobalData’s detailed insights on Savara, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
